The Oncology Tissue Services (OTS) Core provides a number of technologies, services and scientific consultation to support the research of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) members and other Johns Hopkins University (JHU) investigators. The Core was formerly known as the Tissue Microarray Core (TMA), when it provided TMA-related services, digital slide scanning and analysis, and routine histology services. With the addition of immunohistochemistry (IHC), immunofluorescence (IF) in situ hybridization (ISH) and the incorporation of the cytogenetics Core, the Core was renamed. It now provides traditional G-band metaphase analysis and FISH technologies, services added to this Core from a previous SKCCC CCSG Core. These expanded services enhance the ability of SKCCC researchers to perform tissue- based biomarker studies. The OTS Core has constructed greater than 826 TMAs for 55 investigators, containing tumor and normal tissue from most major organs. It has provided more than 80 new antibody workups and cored more than 2,500 blocks for RNA/DNA studies. It continues to provide essential cytogenetics services. Users published more than 104 manuscripts involving this resource since the last funding period began. In recent years, there has been tremendous growth in the service of providing tissue cores from FFPE tissue blocks for RNA and DNA molecular analyses. Instrumentation and expertise are available to automatically capture high-resolution digital images of both standard histology/IHC-based slides and TMA slides. The OTS Core obtained an automated slide stainer to convert laboratory discoveries of novel protein staining into clincal biomarkers. The Core provides Web-based software tools and two back-end databases (TMAJ/Spectrum) to facilitate all facets of research involving TMAs, routine slides and quantitative image analysis.
The specific aims of this Core are:
Aim 1 : Provide affordable, high-quality histology, immunohistochemistry, cytogenetics, nucleic acid harvesting from tissues, digital slide scanning and analysis, and tissue microarray construction services.
Aim 2 : Identify and develop new technologies to support and speed translational research in cancer, including automated in situ hybridization and clinical translation of research immunohistochemistry discoveries.
Aim 3 : Support the Research Programs and respond to the needs of its users to by working with specific investigators on new protocols, procedures and custom procedures to meet their evolving histology, immunohistochemistry and slide scanning requirements. SKCCC Managed Core Reporting Period: Jan. 1, 2015, to Dec. 31, 2015

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-56
Application #
9686690
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
56
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications